Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg 30 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 55 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  2. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  3. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  4. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  5. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  6. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  7. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  8. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  9. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  10. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  11. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  12. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  13. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  14. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  15. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  16. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  17. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  18. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  19. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  20. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  21. Willimsky G, et al. 2021. Elife. 10:. PubMed
  22. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  23. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  24. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  25. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  26. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  27. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  28. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  29. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  30. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  31. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  32. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  33. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  34. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  35. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  36. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  37. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  38. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  39. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  40. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  41. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  42. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  43. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  44. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  45. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  46. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  47. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  48. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  49. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  50. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  51. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  52. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  53. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  54. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  55. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  56. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  57. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  58. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  59. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  60. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  61. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  62. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  63. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  64. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  65. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  66. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  67. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  68. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  69. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  70. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  71. Henrick BM, et al. 2021. Cell. . PubMed
  72. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  73. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  74. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  75. Ardain A, et al. 2019. Nature. 570:528. PubMed
  76. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  77. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  78. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  79. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  80. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  81. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  82. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  83. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  84. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  85. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  86. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  87. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  88. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  89. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  90. Naranbhai V, et al. 2022. Cell. . PubMed
  91. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  92. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  93. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  94. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  95. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  96. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  97. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  98. He Y, et al. 2021. eLife. 10:00. PubMed
  99. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  100. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  101. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  102. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  103. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  104. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  105. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  106. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  107. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 06.12.2013

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Purified anti-human CD3

  • FITC anti-human CD3

  • PE anti-human CD3

  • Alexa Fluor® 488 anti-human CD3

  • Alexa Fluor® 647 anti-human CD3

  • Pacific Blue™ anti-human CD3

  • APC anti-human CD3

  • Biotin anti-human CD3

  • Brilliant Violet 605™ anti-human CD3

  • Brilliant Violet 650™ anti-human CD3

  • Ultra-LEAF™ Purified anti-human CD3

  • Brilliant Violet 711™ anti-human CD3

  • Brilliant Violet 785™ anti-human CD3

  • Brilliant Violet 510™ anti-human CD3

  • PE/Cyanine7 anti-human CD3

  • PerCP/Cyanine5.5 anti-human CD3

  • PerCP anti-human CD3

  • Alexa Fluor® 700 anti-human CD3

  • APC/Cyanine7 anti-human CD3

  • Brilliant Violet 421™ anti-human CD3

  • PE/Dazzle™ 594 anti-human CD3

  • APC/Fire™ 750 anti-human CD3

  • GMP Ultra-LEAF™ Purified anti-human CD3 SF

  • PE/Cyanine5 anti-human CD3 Antibody

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account